Methods and compositions for treating thyroid-related medical conditions with reduced folates

• US 8,575,171 B2
• Filed: 11/28/2012
• Issued: 11/05/2013
• Est. Priority Date: 07/10/2009
• Status: Active Grant

• Current Assignee: Linzy O. Scott III
• Original Assignee: Linzy O. Scott III
• Inventors: Scott, Linzy O. III
• Primary Examiner(s): ALSTRUM ACEVEDO, JAMES HENRY
• Application Number:
  US13/687,109
• Publication Number:
  US 20130089623A1
• Time in Patent Office: 342 Days
• Field of Search: 514/167, 514/22.14, 514/249, 514/502, 514/556, 514/667, 514/904
• US Class Current: 514/252.14
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61K 31/7056 containing five-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/16 for decreasing, blocking or antagonising the activity of the thyroid hormones
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

Claims

1. A method of treating decreased folate in cerebrospinal fluid, comprising:

a. selecting an individual with hyperthyroidism; and

b. administering a composition comprising a folate to the individual.

2. The method of claim 1, wherein the folate is a reduced folate.

3. The method of claim 2, wherein the individual takes or has been exposed to an anti-thyroid drug and the reduced folate is administered with the anti-thyroid drug.

4. The method of claim 3, further comprising administering one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

5. The method of claim 2, wherein the individual takes or has been exposed to an anti-thyroid drug and the reduced folate is administered with vitamin B12 and the anti-thyroid drug.

6. The method of claim 5, further comprising administering one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

7. The method of claim 2, wherein the reduced folate is in a composition comprising an anti-thyroid drug, and one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

8. The method of claim 2, wherein the reduced folate is in a composition comprising an anti-thyroid drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

9. The method of claim 1, wherein the folate is L-methylfolate.

10. The method of claim 9, wherein the individual takes or has been exposed to an anti-thyroid drug and the L-methylfolate is administered with the anti-thyroid drug.

11. The method of claim 10, further comprising administering one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

12. The method of claim 9, wherein the individual takes or has been exposed to an anti-thyroid drug and the L-methylfolate is administered with vitamin B12 and the anti-thyroid drug.

13. The method of claim 12, further comprising administering one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

14. The method of claim 9, wherein the L-methylfolate is in a composition comprising an anti-thyroid drug, and one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

15. The method of claim 9, wherein the L-methylfolate is in a composition comprising an anti-thyroid drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

16. The method of claim 1, further comprising administering vitamin B12 to the individual.

17. The method of claim 1, wherein the individual has a masked megaloblastic anemia.

18. The method of claim 1, wherein the individual has a masked macrocytic anemia.

19. The method of claim 1, wherein the individual has a macrocytic anemia.

20. The method of claim 1, wherein the individual has a normocytic anemia.

21. The method of claim 1, wherein the individual has a microcytic anemia.

22. The method of claim 1, wherein the individual has one or more of the following:

megaloblastic anemia, pancytopenia, aplastic anemia, neutropenia, agranulocytosis, thrombocytopenia, leukopenia, pernicious anemia, or iron deficiency.

23. The method of claim 1, wherein the individual has hepatic dysfunction.

24. The method of claim 1, wherein the individual had hypothyroxinemia.

25. The method of claim 1, wherein the individual has been or is exposed to radioactive iodine or radiation that affects or affected the thyroid gland, or had or has surgery on the thyroid gland.

26. The method of claim 1, wherein the individual takes or has been exposed to an anti-thyroid drug.

27. The method of claim 1, wherein the individual has been exposed to an environmental toxin that impacts the thyroid system or the thyroid of the individual.

28. The method of claim 1, wherein the individual has a methylenetetrahydrofolate reductase polymorphism.

29. The method of claim 1, further comprising administering iron to the individual.

30. The method of claim 1, further comprising administering L-carnitine to the individual.

31. The method of claim 1, further comprising administering calcium to the individual.

32. The method of claim 1, further comprising administering vitamin D to the individual.

33. The method of claim 1, further comprising administering vitamin B12 and iron to the individual.

34. The method of claim 1, further comprising administering vitamin B12 and L-carnitine to the individual.

35. The method of claim 1, further comprising administering vitamin B12 and calcium to the individual.

36. The method of claim 1, further comprising administering vitamin B12 and vitamin D to the individual.

37. The method of claim 1, wherein the composition further comprises one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

38. The method of claim 1, wherein the composition further comprises vitamin B12 and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

39. The method of claim 1, wherein the individual takes or has been exposed to an anti-thyroid drug and the folate is administered with the anti-thyroid drug.

40. The method of claim 39, further comprising administering one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

41. The method of claim 1, wherein the individual takes or has been exposed to an anti-thyroid drug and the folate is administered with vitamin B12 and the anti-thyroid drug.

42. The method of claim 41, further comprising administering one or more of the following:

iron, L-carnitine, calcium, or vitamin D.

43. The method of claim 1, wherein the folate is in a composition comprising an anti-thyroid drug, and one or more of the following:

vitamin B12, iron, L-carnitine, calcium, or vitamin D.

44. The method of claim 1, wherein the folate is in a composition comprising an anti-thyroid drug, vitamin B12, and one or more of the following:

iron, L-carnitine, calcium, or vitamin D.